Latest Industrial Materials News

Volt Resources has initiated a Definitive Feasibility Study for its Alabama Graphite Refinery, aiming to produce high purity graphite by mid-2026 and strengthen US critical minerals supply chains.

ALS Limited reported a robust half-year performance with underlying revenue up 13.3% and net profit after tax rising 17.2%, driven by strong growth in both Commodities and Life Sciences divisions. The company also declared a higher interim dividend and advanced its global expansion strategy.

Eden Innovations has completed the sale of its Georgia property for US$5 million, using the proceeds to significantly reduce its debt and edge closer to completing its financial reconstruction.

First Graphene has completed its initial industrial-scale shipment of graphene-enhanced TPU masterbatch to PT Alasmas, marking a key milestone in commercialising advanced materials for durable work boots in Southeast Asia.

Pacific Lime and Cement Limited has taken a decisive step forward with the Final Investment Decision for its Central Lime Project in Papua New Guinea, initiating full-scale construction and early sales. The company also advances renewable energy plans and strategic rebranding to solidify its regional presence.

NOVONIX has delivered its first commercial-grade synthetic graphite sample at mass production scale, marking a key step toward expanding its battery and industrial materials footprint.

Australian Rare Earths Limited (ASX, AR3) reports successful metallurgical testwork at its Koppamurra Rare Earths Project, producing 34kg of Mixed Rare Earth Oxide from heap leach solutions, paving the way for streamlined, cost-effective rare earth processing.

Nanollose Limited has appointed Andrew Moullin as its new CEO and Managing Director, aiming to leverage his extensive commercial expertise to fast-track the company’s microbial cellulose technology towards market readiness.

ALS Limited has announced a fully underwritten A$350 million equity placement to fund major upgrades to its global laboratory network and support future growth initiatives, aiming for mid single-digit EPS accretion by FY25 pro forma.

ALS Limited delivered a robust FY25 performance with 16% revenue growth to $3 billion and underlying EBIT rising 4.7% to $515 million, driven by strong organic growth and strategic acquisitions. The company is advancing its Nuvisan integration ahead of schedule and has unveiled a $230 million investment plan to expand key laboratories, positioning itself for sustained growth amid market uncertainties.

ALS Limited reported a robust FY25 with $3 billion revenue driven by Life Sciences growth and resilient Commodities, announcing a $350 million equity raise to fund strategic expansion.